Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Personalis Inc    PSNL

PERSONALIS INC

(PSNL)
  Report  
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector news

Personalis, Inc. : to Provide Comprehensive Tumor Immunogenomic Profiling to the New Mexico Cancer Care Alliance for Clinical Study

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/07/2019 | 08:06am EDT

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that The University of New Mexico (UNM) Comprehensive Cancer Center and the New Mexico Alliance for Cancer Care will utilize Personalis’ cancer immunogenomics platform, ImmunoID NeXT™, for the investigation of biomarkers of response to a novel treatment paradigm in women with ovarian cancer. The basis of this trial, which evaluates the combination of Olaparib and Tremelimumab in women with recurrent BRCA-deficient ovarian cancers, is based on the work of Sarah Adams, MD, that indicated that immune priming with targeted cytotoxic therapy using a PARP-inhibitor can sensitize ovarian tumors to immune therapy and optimize patient survival. The clinical trial is being conducted at several ORIEN centers across the United States. For more information please visit clinicaltrials.gov identifier NCT02571725.

“We are delighted to collaborate with Personalis on this study,” said the principal investigator of the study, Dr. Adams, Associate Professor, Division of Gynecologic Oncology at the UNM Comprehensive Cancer Center. “Comprehensive immuno-profiling will inform on biomarkers of response for this experimental treatment in women with BRCA1 or BRCA2 germline mutated ovarian cancers, for which there aren’t standard curative measures.”

Personalis ImmunoID NeXT™ Platform provides a comprehensive interrogation and analysis of ~20,000 genes in both DNA and RNA. The platform is an end-to-end solution for immuno- and precision oncology biomarker discovery applications, simultaneously enabling the analysis of: tumor escape mechanisms (including HLA typing and somatic mutation detection), immune repertoire profiles, neoantigen load, tumor mutational burden (TMB), microsatellite instability (MSI), oncoviruses, and immune checkpoint gene expression.

About Personalis, Inc.

Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. The company’s NeXT™ Platform is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. The Personalis Clinical Laboratory is GxP aligned as well as CLIA’88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter (@PersonalisInc).


© Business Wire 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PERSONALIS INC
09/12PERSONALIS : Appoints Karin Eastham to Its Board of Directors
BU
09/12PERSONALIS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
09/09PERSONALIS, INC. : Enters Into Research Agreement With Invectys to Provide Compr..
BU
08/26PERSONALIS : to Participate in the 17th Annual Morgan Stanley Global Healthcare ..
BU
08/13PERSONALIS : Management's Discussion and Analysis of Financial Condition and Res..
AQ
08/13PERSONALIS : 2Q Earnings Snapshot
AQ
08/13PERSONALIS, INC. : Results of Operations and Financial Condition, Financial Stat..
AQ
08/13PERSONALIS : Reports Second Quarter 2019 Financial Results
BU
08/07PERSONALIS, INC. : to Provide Comprehensive Tumor Immunogenomic Profiling to the..
BU
08/01PERSONALIS, INC. : Announces Integration of New ImmunoID NeXT Platform™ Fe..
BU
More news
Financials (USD)
Sales 2019 61,7 M
EBIT 2019 -24,8 M
Net income 2019 -26,3 M
Finance 2019 128 M
Yield 2019 -
P/E ratio 2019 -14,3x
P/E ratio 2020 -17,3x
EV / Sales2019 6,09x
EV / Sales2020 5,02x
Capitalization 503 M
Chart PERSONALIS INC
Duration : Period :
Personalis Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PERSONALIS INC
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 27,33  $
Last Close Price 16,16  $
Spread / Highest target 79,5%
Spread / Average Target 69,1%
Spread / Lowest Target 60,9%
EPS Revisions
Sector and Competitors
1st jan.Capitalization (M$)
PERSONALIS INC0.00%503
IQVIA HOLDINGS INC31.65%29 960
LONZA GROUP32.98%25 321
CELLTRION, INC.--.--%18 395
INCYTE CORPORATION23.20%17 012
EXACT SCIENCES CORPORATION69.37%13 838